MedTrace Logo

A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor

NCT07140393 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-08-24

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combination with other anti tumor therapy in subjects with solid tumor ; to evaluate HRS4508 DLT, MTD and RP2D, to evaluate the incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0), to evaluate ORR by researchers based on RECIST v1.1, to evaluate the pharmacokinetic (PK) characteristics of HRS-4508 SHR-1811, Capecitabine.

Conditions

Interventions

DRUG

HRS-4508+ Capecitabine

HRS-4508+ Capecitabine

DRUG

HRS-4508+ Trastuzumab

HRS-4508+ Trastuzumab

DRUG

HRS-4508+ Trastuzumab+ Pertuzumab

HRS-4508+ Trastuzumab+ Pertuzumab

DRUG

HRS-4508+ Trastuzumab+ Capecitabine

HRS-4508+ Trastuzumab+ Capecitabine

DRUG

Trastuzumab+ Capecitabine

Trastuzumab+ Capecitabine

DRUG

HRS-4508+A1811

HRS-4508+A1811

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-31
Primary Completion
2027-10-31
Completion
2028-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07140393 on ClinicalTrials.gov